The European Commission (EC) began a call for evidence on May 14, 2025, for an impact assessment of the European Biotech Act. The EC states that the overall objective is to improve the size and competitiveness of the biotechnology sector in the European Union (EU) while maintaining high safety standards. The new European Biotech Act will aim to ensure that the EU makes the most of the biotechnology revolution for the benefit of society, the environment, and the economy, while making it easier to develop and bring to market products across all biotechnology sectors in the EU. According to the EC, the European Biotech Act would address the following issues: • European companies have difficulty expanding within the single market because of “a complex regulatory framework that is perceived a

See Full Page